1806. Fluoroquinolone-Resistant Escherichia coli Infections after Transrectal Biopsy of the Prostate in the Veterans Affairs Healthcare System
Session: Poster Abstract Session: Resistant Gram-Negative Infections: Epidemiology
Saturday, October 10, 2015
Room: Poster Hall
  • TBP poster revised.pdf (366.0 kB)
  • Background: Recent reports suggest that infections due to fluoroquinolone-resistant Escherichia coli (FREC) are an increasingly common complication of transrectal biopsy of the prostate (TBP) in the United States.  A better understanding of the magnitude and scope these infections is needed to guide prevention efforts. Our objectives are to determine if the incidence of infections due to FREC after TBP has increased nationwide in the Veterans Affairs Healthcare System (VAHS) and to identify risk factors for infection.

    Methods: Using national VAHS databases, we retrospectively identified patients undergoing TBP between 1/1/2000 and 12/31/2013 and determined the incidence of Urinary Tract Infections (UTI) and bacteremia with E. coli and of FREC within 30 days after TBP. We also determined the proportion of all E. coli urinary and blood isolates that were resistant to fluoroquinolones during the same time period. A nested case-control study of patients undergoing TBP from 2011 through 2013 was conducted to identify risk factors for infection with FREC.

    Results: 245,618 patients undergoing 302,168 TBP procedures from 2000 through 2013 were included in the cohort study, and 59,469 patients undergoing TBP from 2011 through 2013 were included in the nested case-control study.  Figure 1 shows the incidence of post-TBP UTI due to E. coli, stratified by fluoroquinolone susceptibility, and the concurrent yearly prevalence of fluoroquinolone resistance in all E. coli urinary isolates.  Between 2000 and 2013, there was a five-fold increase in the incidence of E. coli UTI (0.18% to 0.93%) and four-fold increase in the incidence of E. coli bacteremia (0.04% to 0.18%) after TBP that was attributable to an increase in the incidence of FREC UTI (0.03% to 0.75%) and bacteremia (0.01% to 0.14%). This occurred in parallel with increasing rates of fluoroquinolone-resistance in all E. coli isolates. By multivariable logistic regression analysis, independent risk factors for FREC UTI after TBP included diabetes mellitus, fluoroquinolone exposure, prior hospitalization, and prior cultures with fluoroquinolone-resistant gram-negative bacilli.

    Conclusion: In the VAHS, the incidence of E. coli infection after TBP has increased significantly since 2000 due to a dramatic rise in infections with FREC.

    Elie Saade, MD, MPH, Infectious Diseases, University Hospitals of Cleveland, Cleveland, OH, Nuntra Suwantarat, MD, Medicine, University Hospitals Case Medical Center, Cleveland, OH, Brigid Wilson, PhD, Geriatric Research, Education, and Clinical Center, Cleveland Vet. Medical Center, Cleveland, OH, Trina Zabarsky, RN, CNP, Infectious Diseases, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH and Curtis J. Donskey, MD, Infectious Diseases, Case Western Reserve University, Cleveland, OH


    E. Saade, None

    N. Suwantarat, None

    B. Wilson, None

    T. Zabarsky, None

    C. J. Donskey, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.